Sorrento Presents Preliminary Results of STI-2020 Against COVID-19
ITROM Pharmaceutical Signs an Exclusive License & Commercialization Agreement with Mithra for 20 years
ITROM Pharmaceutical Signs an Exclusive License & Commercialization Agreement with Mithra for 20 years
Shots:
- ITROM to get exclusive commercialization rights for Mithra’s Myring in MENA territories (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman, Lebanon, and Jordan) with a total deal value of $6.79M. Mithra strengthen its portfolio and manufacture it at CDMO facility in Belgium
- The focus of the agreement is to develop and commercialize techniques for women in fields of fertility, contraception, Hormonal Therapy (HT) & personal care and generate $15.8M in combination with their deal, in Dec 2018 to commercialize Mithra’s Tibelia and Daphne Continu
- Myring (etonogestrel, 11.7mg /ethinyl estradiol,2.7mg) is a generic of NuvaRing a contraceptive vaginal ring, made of ethylene vinyl acetate copolymers for the prevention of pregnancy
Click here to read full press release/ article | Ref: Mithra | Image: Mithra